Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9,720 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Single-cell transcriptome analysis reveals functional changes in tumour-infiltrating B lymphocytes after chemotherapy in oesophageal squamous cell carcinoma.
Nakamura S, Ohuchida K, Ohtsubo Y, Yamada Y, Tsutsumi C, Okuda S, Hisano K, Mochida Y, Shinkawa T, Iwamoto C, Torata N, Mizuuchi Y, Shindo K, Nakata K, Moriyama T, Torisu T, Nagai E, Morisaki T, Kitazono T, Oda Y, Nakamura M. Nakamura S, et al. Among authors: yamada y. Clin Transl Med. 2023 Jan;13(1):e1181. doi: 10.1002/ctm2.1181. Clin Transl Med. 2023. PMID: 36650114 Free PMC article.
Prognostic value of morphological characteristics assessed by CT scan in patients with non-small cell lung cancer treated with nivolumab.
Minemura H, Moriya H, Imai H, Sugiyama T, Yamada Y, Higuchi M, Kaira K, Ozaki Y, Kanazawa K, Yokouchi H, Kasai T, Kaburagi T, Suzuki H, Minato K, Shibata Y. Minemura H, et al. Among authors: yamada y. Thorac Cancer. 2020 Dec;11(12):3521-3527. doi: 10.1111/1759-7714.13695. Epub 2020 Oct 12. Thorac Cancer. 2020. PMID: 33044045 Free PMC article.
Efficacy and safety of cytotoxic drug chemotherapy after first-line EGFR-TKI treatment in elderly patients with non-small-cell lung cancer harboring sensitive EGFR mutations.
Imai H, Minemura H, Sugiyama T, Yamada Y, Kaira K, Kanazawa K, Kasai T, Kaburagi T, Minato K; Gunma-Ibaraki-Fukushima-Tochigi (GIFT) Group. Imai H, et al. Among authors: yamada y. Cancer Chemother Pharmacol. 2018 Jul;82(1):119-127. doi: 10.1007/s00280-018-3596-6. Epub 2018 May 8. Cancer Chemother Pharmacol. 2018. PMID: 29737372
Pretreatment Glasgow prognostic score predicts survival among patients with high PD-L1 expression administered first-line pembrolizumab monotherapy for non-small cell lung cancer.
Imai H, Kishikawa T, Minemura H, Yamada Y, Ibe T, Yamaguchi O, Mouri A, Hamamoto Y, Kanazawa K, Kasai T, Kaira K, Kaburagi T, Minato K, Kobayashi K, Kagamu H. Imai H, et al. Among authors: yamada y. Cancer Med. 2021 Oct;10(20):6971-6984. doi: 10.1002/cam4.4220. Epub 2021 Aug 20. Cancer Med. 2021. PMID: 34414673 Free PMC article.
Post-progression survival after atezolizumab plus carboplatin and etoposide as first-line chemotherapy in small cell lung cancer has a significant impact on overall survival.
Masubuchi K, Imai H, Wasamoto S, Tsuda T, Minemura H, Nagai Y, Yamada Y, Kishikawa T, Umeda Y, Shiono A, Takechi H, Shiihara J, Kaira K, Kanazawa K, Taniguchi H, Kaburagi T, Kagamu H, Minato K. Masubuchi K, et al. Among authors: yamada y. Thorac Cancer. 2022 Oct;13(19):2776-2785. doi: 10.1111/1759-7714.14621. Epub 2022 Sep 5. Thorac Cancer. 2022. PMID: 36062426 Free PMC article.
Clinical Impact of Post-Progression Survival on Overall Survival in Elderly Patients with Non-Small-Cell Lung Cancer Harboring Sensitive EGFR Mutations Treated with First-Line EGFR Tyrosine Kinase Inhibitors.
Imai H, Yamada Y, Sugiyama T, Minemura H, Kaira K, Kanazawa K, Kasai T, Kaburagi T, Minato K; Gunma-Ibaraki-Fukushima-Tochigi (GIFT) group. Imai H, et al. Among authors: yamada y. Chemotherapy. 2018;63(3):181-189. doi: 10.1159/000490949. Epub 2018 Aug 14. Chemotherapy. 2018. PMID: 30107372
A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer -TCOG 1101.
Kasai T, Mori K, Kishi K, Kaburagi T, Hosomi Y, Imai H, Yamada Y, Yomota M, Moriguchi S, Seike M, Minato K, Gemma A; Tokyo Cooperative Oncology Group. Kasai T, et al. Among authors: yamada y. Int J Clin Oncol. 2020 May;25(5):867-875. doi: 10.1007/s10147-020-01629-6. Epub 2020 Feb 14. Int J Clin Oncol. 2020. PMID: 32060768 Clinical Trial.
Real-world data of atezolizumab plus carboplatin and etoposide in elderly patients with extensive-disease small-cell lung cancer.
Shiono A, Imai H, Wasamoto S, Tsuda T, Nagai Y, Minemura H, Yamada Y, Kishikawa T, Umeda Y, Takechi H, Yamaguchi O, Mouri A, Kaira K, Taniguchi H, Minato K, Kagamu H. Shiono A, et al. Among authors: yamada y. Cancer Med. 2023 Jan;12(1):73-83. doi: 10.1002/cam4.4938. Epub 2022 Jun 14. Cancer Med. 2023. PMID: 35699088 Free PMC article.
Clinicopathological Features in Elderly ALK-rearranged Non-small Cell Lung Cancer Patients.
Miyazaki K, Sato S, Kodama T, Numata T, Endo T, Yamamoto Y, Shimizu K, Yamada H, Hayashihara K, Okauchi S, Satoh H, Yamada Y, Tamura T, Saito K, Kikuchi N, Kurishima K, Ishikawa H, Watanabe H, Shiozawa T, Hizawa N, Funayama Y, Hayashi S, Nakamura H, Yamashita T. Miyazaki K, et al. Among authors: yamada h, yamada y. In Vivo. 2020 Jul-Aug;34(4):2001-2007. doi: 10.21873/invivo.11998. In Vivo. 2020. PMID: 32606173 Free PMC article.
9,720 results